Friday 6 November 2026
Export ENOV’s income statement to Excel — free account
Enovis Corporation
ENOV Healthcare Medical Devices
Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024.
- Revenue
- +1.79%
- EPS
- +100.6%
- Free cash flow
- +20.3%
- Total debt
- −7.45%
Quarter to September 2026, against a year earlier
27.07
1.55
−5.42%
Follow ENOV
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 4 | 4 |
+8 more TTM periods Free account |
| (29.97%) | (54.27%) | (55.48%) | (58.40%) | ||
| (12.91%) | (25.07%) | (26.12%) | (27.69%) | ||
ROIC |
(10.83%) | (23.55%) | (24.14%) | (25.53%) | |
Return on Tangible Assets |
(44.17%) | (97.48%) | (98.83%) | (106.17%) | |
Average Days of Receivables |
67.78 | 70.22 | 71.16 | 71.89 | |
Free Cash Flow per Share |
1.19 | 1.11 | 0.63 | 0.35 | |
Free Cash Flow |
69.56 | 63.66 | 35.92 | 19.92 | |
Capital Expenditures |
(189.46) | (206.44) | (206.92) | (197.38) | |
| Other line items | |||||
Cash ROIC |
2.51% | 2.29% | 1.27% | 0.71% | |
Accounts Receivable Turnover |
5.36 | 5.13 | 5.18 | 5.29 | |
Accounts Payable Turnover |
4.47 | 4.40 | 4.48 | 4.92 | |
Inventory Turnover |
1.45 | 1.45 | 1.51 | 1.60 | |
Average Days of Payables |
81.98 | 79.44 | 86.65 | 75.82 | |
Days of Inventory on Hand |
253.65 | 245.77 | 244.41 | 236.27 | |
Tax Rate |
0.05 | 0.03 | 0.03 | 0.02 | |
Research and Development Expense of Revenue |
5.46% | 5.41% | 5.41% | 5.35% | |
Selling, General and Administrative Expense of Revenue |
46.67% | 47.05% | 47.58% | 47.60% | |
Share Based Compensation of Revenue |
1.46% | 1.51% | 1.50% | 1.46% | |
Interest Coverage |
(14.69) | (30.90) | (30.77) | (32.28) | |
Operating CF/Net income |
(0.49) | (0.25) | (0.21) | (0.18) | |
Depreciation/Fixed assets |
0.00 | 2.55 | 2.59 | 2.65 | |
Capex/Depreciation |
0.00 | (0.15) | (0.15) | (0.15) | |
Revenue per Share |
39.43 | 39.87 | 39.75 | 39.39 | |
Operating CF per Share |
4.43 | 4.69 | 4.24 | 3.81 | |
Capex per Share |
(3.24) | (3.58) | (3.61) | (3.46) | |
Capex to Sales |
0.08 | 0.09 | 0.09 | 0.09 |
Columns are period end dates · fundamentals updated 5 Nov 2026